glp 1 and alcohol cravings A preliminary study of the physiological perceptual effects of GLP-1 receptor agonists during consumption in people with obesity How GLP-1 Drugs Are Impacting

A plastic surgeon does both better than a non-specialist

Colburn, Z

Some patients report a pale or yellowish tinge to the skin, and glossitis (a sore, red tongue) may develop

Age was only considered for inclusion and exclusion criteria

2 RESEARCH METHODOLOGY 54 5.2.1.1 SURGE IN DEMAND FOR COMPLEX APIS 84 5.2.1.2 FAVORABLE GOVERNMENT INCENTIVES AND SUPPLY CHAIN RESHORING 84 5.2.1.3 INCREASING ADOPTION OF CONTINUOUS MANUFACTURING AND DIGITAL PROCESS CONTROLS 85 5.2.1.4 RAPID GROWTH OF ONCOLOGY AND RARE DISEASE PIPELINES 86 5.2.2.1 TIGHTENING REGULATORY REQUIREMENTS FOR NITROSAMINE AND IMPURITY CONTROLS 88 5.2.2.2 HIGH PRODUCTION COSTS IN US AND EUROPE-BASED FACILITIES 89 5.2.2.3 PRICE PRESSURE FROM GENERIC TENDERS AND SINGLE-WINNER PROCUREMENT POLICIES 89 5.2.3.1 GROWING EMPHASIS ON SUPPLY RESILIENCE AND SECURITY OF CRITICAL MEDICINE MANUFACTURING 89 5.2.3.2 CHINA-PLUS-ONE STRATEGY 90 5.2.3.3 INCREASING ADOPTION OF INTEGRATED CDMO SERVICE MODELS 90 5.2.4.1 CAPITAL-INTENSIVE INVESTMENTS FOR HIGH CONTAINMENT AND ADVANCED FACILITIES 91 5.2.4.2 QUALITY FAILURES AND SITE SHUTDOWNS 91 5.2.4.3 SUPPLY CHAIN CONCENTRATION RISK 91 5.2.4.4 GEOPOLITICAL TENSIONS AND TRADE RESTRICTIONS 92 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS 92 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024 93 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 95 5.5 TECHNOLOGY ANALYSIS 96 5.5.1 KEY TECHNOLOGIES 96 5.5.1.1 CONTINUOUS MANUFACTURING 96 5.5.1.2 ADVANCED ANALYTICAL TECHNIQUES 97 5.5.2 COMPLEMENTARY TECHNOLOGIES 97 5.5.2.1 DATA ANALYTICS AND DIGITALIZATION 97 5.5.2.2 PERSONALIZED MEDICINES AND CUSTOM SYNTHESIS 97 5.5.2.3 SUPERCRITICAL FLUID TECHNOLOGY 98 5.5.3 ADJACENT TECHNOLOGIES 98 5.5.3.1 SUPPLY CHAIN VISIBILITY AND BLOCKCHAIN 98 5.5.3.3 NANOTECHNOLOGY 99 5.6 SUPPLY CHAIN ANALYSIS 99 5.7 VALUE CHAIN ANALYSIS 100 5.7.1 RESEARCH & DEVELOPMENT (VALUE ADDITION: 3035%) 101 5.7.2 CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 5070%) 102 5.7.3 MANUFACTURING (VALUE ADDITION: 7080%) 102 5.7.4 MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80100%) 102 5.8 ECOSYSTEM ANALYSIS 102 5.9 KEY CONFERENCES & EVENTS 104 5.10 REGULATORY ANALYSIS 105 5.10.1 REGULATORY SCENARIO 106 5.10.1.1 NORTH AMERICA 106 5.10.1.3 ASIA PACIFIC 107 5.10.1.4 LATIN AMERICA 107 5.10.1.5 MIDDLE EAST & AFRICA 107 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 5.11 PORTERS FIVE FORCES ANALYSIS 110 5.11.1 THREAT OF NEW ENTRANTS 112 5.11.2 THREAT OF SUBSTITUTES 112 5.11.3 BARGAINING POWER OF SUPPLIERS 112 5.11.4 BARGAINING POWER OF BUYERS 112 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 112 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 113 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 113 5.12.2 KEY BUYING CRITERIA 114 5.13 CASE STUDY ANALYSIS 115 5.14 MACROECONOMICS INDICATORS 116 5.14.1 HEALTHCARE EXPENDITURE TRENDS 116 5.14.2 GLOBAL CANCER BURDEN 117 5.15.1 LIST OF PATENTS 120 5.16 UNMET NEEDS AND WHITE SPACES 120 5.17.1 IMPORT DATA FOR HS CODE2941 121 5.17.2 EXPORT DATA FOR HS CODE2941 124 5.18 INVESTMENT AND FUNDING SCENARIO 127 5.19 MANUFACTURING SITES AND CAPACITY EXPANSION OF KEY API SUPPLIERS 128 5.20 IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 131 5.20.2 IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 131 5.20.4 FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM 133 5.21 IMPACT OF US TARIFF ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 134 5.21.2 KEY TARIFF RATES 134 5.21.3 PRICE IMPACT ANALYSIS 135 5.21.4 IMPACT ON COUNTRY/REGION 136 5.21.4.1 NORTH AMERICA 136 5.21.4.3 ASIA PACIFIC 136 5.21.5 IMPACT ON END-USE INDUSTRIES 136 5.21.5.1 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 136 5.21.5.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 137 5.21.5.3 CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 137 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 138 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 139 6.3.1 INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH 140 6.4.1 GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET 144 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 148 7.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT) 149 7.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH 150 7.4 HIGHLY POTENT APIS 154 7.4.1.1 EVOLVING TARGETED ONCOLOGY THERAPIES TO STIMULATE GROWTH 158 7.4.2.1 ROBUST PRODUCT PIPELINE TO ENCOURAGE GROWTH 161 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 165 8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT) 166 8.3.1 INNOVATIVE SYNTHETIC APIS 171 8.3.1.1 HIGH VALUE OF INNOVATIVE APIS TO DRIVE MARKET 171 8.3.2 GENERIC SYNTHETIC APIS 175 8.3.2.1 INCREASING NEED FOR GENERIC MEDICINES TO CONTRIBUTE TO GROWTH 175 8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 182 8.4.1.1 INNOVATIVE BIOTECH APIS 182 8.4.1.2 GENERIC BIOTECH APIS 186 8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 190 8.4.2.1 MONOCLONAL ANTIBODIES 190 8.4.2.2 HORMONES AND GROWTH FACTORS 194 8.4.2.3 FUSION PROTEINS 197 8.4.2.5 THERAPEUTIC ENZYMES 203 8.4.2.6 BLOOD FACTORS AND ANTI-COAGULANTS 206 8.4.2.7 RECOMBINANT VACCINES 209 8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 212 8.4.3.1 MAMMALIAN EXPRESSION SYSTEMS 213 8.4.3.2 MICROBIAL EXPRESSION SYSTEMS 217 8.4.3.3 YEAST EXPRESSION SYSTEMS 220 8.4.3.4 INSECT EXPRESSION SYSTEMS 224 8.4.3.5 OTHER EXPRESSION SYSTEMS 228 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 231 9.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT) 232 9.3 PRESCRIPTION DRUGS 233 9.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH 233 9.4 OVER-THE-COUNTER DRUGS 237 9.4.1 RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH CONCERNS TO SPUR GROWTH 237 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 241 10.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT) 242 10.3 COMMUNICABLE DISEASES 244 10.3.1 INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS, ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH 244 10.4.1 GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET 247 10.5.1 RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH 251 10.6 CARDIOVASCULAR DISEASES 255 10.6.1 INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH 255 10.7 RESPIRATORY DISEASES 258 10.7.1 INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH 258 10.8.1 RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH 262 10.9 OTHER THERAPEUTIC APPLICATIONS 265 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER 269 11.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT) 270 11.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 272 11.3.1 RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH 272 11.4 CONTRACT RESEARCH ORGANIZATIONS 275 11.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH 275 11.5 CONTRACT MANUFACTURING ORGANIZATIONS 279 11.5.1 GROWING FOCUS ON BETTER QUALITY AND REGULATORY COMPLIANCE TO DRIVE MARKET 279 12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 286 12.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT) 287 12.3.1 MACROECONOMIC ANALYSIS OF NORTH AMERICA 290 12.3.2.1 HIGH CLINICAL TRIAL & DRUG DISCOVERY ACTIVITY AND EFFICIENT REGULATORY ENVIRONMENT TO EXPEDITE GROWTH 296 12.3.3.1 FAVORABLE GOVERNMENT SUPPORT AND STRONG PRODUCT PIPELINE TO SUSTAIN GROWTH 301 12.4.1 MACROECONOMIC ANALYSIS OF EUROPE 307 12.4.2.1 HIGH HEALTHCARE EXPENDITURE AND ADVANCED R&D FACILITIES TO DRIVE MARKET 313 12.4.3.1 RISING GOVERNMENT INVESTMENTS AND GROWING FOCUS ON PERSONALIZED TREATMENT TO FUEL MARKET 318 12.4.4.1 INCREASED FOCUS ON DOMESTIC MANUFACTURING TO PROMOTE GROWTH 323 12.4.5.1 RISING COMMERCIAL DRUG DEVELOPMENT TO FAVOR GROWTH 328 12.4.6.1 INCREASE IN GENERIC DRUG MANUFACTURING CAPACITY TO PROPEL MARKET 333 12.4.7.1 INCREASING MANUFACTURING ACTIVITIES IN PHARMACEUTICAL SECTOR TO DRIVE MARKET 338 12.4.8 REST OF EUROPE 343 12.5.1 MACROECONOMIC ANALYSIS OF ASIA PACIFIC 349 12.5.2.1 RISE IN GOVERNMENT POLICIES TO INCREASE MEDICINE ACCESS AND AFFORDABILITY TO SUPPORT GROWTH 355 12.5.3.1 GROWING GERIATRIC POPULATION TO BOOST MARKET 360 12.5.4.1 INCREASING R&D ACTIVITIES AND RISING GOVERNMENT FUNDING INITIATIVES TO FAVOR GROWTH 365 12.5.5.1 RISING ANNUAL DRUG EXPORTS TO DRIVE MARKET 370 12.5.6.1 INCREASING DEMAND FOR INNOVATIVE APIS TO PROPEL MARKET 375 12.5.7 REST OF ASIA PACIFIC 380 12.6.1 LATIN AMERICA: MACROECONOMIC ANALYSIS 385 12.6.2.1 INCREASED GOVERNMENT INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET 391 12.6.3.1 RISING INVESTMENTS BY FOREIGN FIRMS TO SUPPORT MARKET GROWTH 396 12.6.4 REST OF LATIN AMERICA 401 12.7.1 MACROECONOMIC ANALYSIS OF MIDDLE EAST 406 12.7.2.1 HIGHLY EDUCATED WORKFORCE AND STRONG CULTURE OF INNOVATIONS TO SUPPORT GROWTH 412 12.7.3.1 SAUDI ARABIA 422 12.7.3.3 REST OF GCC COUNTRIES 432 12.7.4 REST OF MIDDLE EAST 437 12.8.1 GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET 442 12.8.2 MACROECONOMIC OUTLOOK FOR AFRICA 442 13 COMPETITIVE LANDSCAPE 449 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 449 13.3 REVENUE ANALYSIS, 20222024 451 13.4 MARKET SHARE ANALYSIS, 2024 452 13.5 COMPANY VALUATION AND FINANCIAL METRICS 454 13.5.1 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 455 13.6 BRAND/PRODUCT COMPARISON 456 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 458 13.7.2 EMERGING LEADERS 458 13.7.3 PERVASIVE PLAYERS 458 13.7.5 COMPETITIVE BENCHMARKING, 2024 460 13.7.5.1 COMPANY FOOTPRINT 460 13.7.5.2 REGION FOOTPRINT 461 13.7.5.3 TYPE FOOTPRINT 462 13.7.5.4 POTENCY FOOTPRINT 463 13.7.5.5 THERAPEUTIC APPLICATION FOOTPRINT 464 13.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 466 13.8.1 PROGRESSIVE COMPANIES 466 13.8.2 RESPONSIVE COMPANIES 466 13.8.3 DYNAMIC COMPANIES 466 13.8.4 STARTING BLOCKS 466 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 468 13.8.5.1 DETAILED LIST OF KEY STARTUPS/SMES 468 13.8.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 470 13.9 COMPETITIVE SCENARIO 471 13.9.1 PRODUCT APPROVALS 471 14.1.1.1 BUSINESS OVERVIEW 476 14.1.1.2 PRODUCTS OFFERED 477 14.1.1.3 RECENT DEVELOPMENTS 479 14.1.2 DIVIS LABORATORIES LIMITED 481 14.1.2.1 BUSINESS OVERVIEW 481 14.1.2.2 PRODUCTS OFFERED 482 14.1.2.3 RECENT DEVELOPMENTS 483 14.1.3.1 BUSINESS OVERVIEW 485 14.1.3.2 PRODUCTS OFFERED 486 14.1.3.3 RECENT DEVELOPMENTS 487 14.1.4.1 BUSINESS OVERVIEW 489 14.1.4.2 PRODUCTS OFFERED 490 14.1.4.3 RECENT DEVELOPMENTS 492 14.1.5.1 BUSINESS OVERVIEW 494 14.1.5.2 PRODUCTS OFFERED 495 14.1.5.3 RECENT DEVELOPMENTS 496 14.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD

D.StrucchiC.LuisiM.CasarosaE.LanzoniC.BaraldiE.et al (2009)